John Farquhar, chief executive of Heartflow, a US-based medical imaging company known for its non-invasive coronary artery disease diagnostics, has sold $626,095 (£484,000) worth of company stock, according to a regulatory filing. The transaction was disclosed on 16 July 2026, though the exact sale date was not specified in the filing.
The sale represents a notable disposal by the company’s top executive, though it is not uncommon for C-suite leaders to reduce holdings for personal tax or estate planning purposes. Heartflow, which is listed on the Nasdaq, has seen its share price decline approximately 18% over the past six months, mirroring a wider pullback in growth-oriented healthcare technology stocks.
For UK investors with exposure to US medtech through pension funds or exchange-traded funds, insider transactions such as this are monitored as potential signals of management confidence. However, analysts caution that a single insider sale should not be over-interpreted. “CEO stock sales are often pre-planned under trading plans, and without context it is difficult to draw firm conclusions about the company’s outlook,” said one London-based healthcare analyst who asked not to be named.
Heartflow’s technology uses AI-powered software to create 3D models of coronary arteries from CT scans, helping doctors diagnose heart disease without invasive procedures. The company has faced competitive pressure from rival imaging firms and broader headwinds in the digital health space, where valuations have cooled since the pandemic-era boom.
The FTSE 100 edged 0.3% higher on Friday, closing at 8,245 points, while the FTSE 250 added 0.2% to 20,710. The pound traded at $1.29 against the US dollar, meaning movements in US-listed stocks have a direct currency impact on UK-based holders. For UK pension savers with international equity allocations, any sustained weakness in Heartflow or similar medtech names could weigh on portfolio returns, though diversified funds typically limit single-stock risk.